Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Reorganization and stability for motor and language areas using cortical stimulation: case example and review of the literature.

Brain sciences

Serafini S, Komisarow JM, Gallentine W, Mikati MA, Bonner MJ, Kranz PG, Haglund MM, Grant G.
PMID: 24961623
Brain Sci. 2013 Nov 26;3(4):1597-614. doi: 10.3390/brainsci3041597.

The cerebral organization of language in epilepsy patients has been studied with invasive procedures such as Wada testing and electrical cortical stimulation mapping and more recently with noninvasive neuroimaging techniques, such as functional MRI. In the setting of a...

Cite
Serafini S, Komisarow JM, Gallentine W, et al. Reorganization and stability for motor and language areas using cortical stimulation: case example and review of the literature. Brain Sci. 2013;3(4):1597-614doi: 10.3390/brainsci3041597.
Serafini, S., Komisarow, J. M., Gallentine, W., Mikati, M. A., Bonner, M. J., Kranz, P. G., Haglund, M. M., & Grant, G. (2013). Reorganization and stability for motor and language areas using cortical stimulation: case example and review of the literature. Brain sciences, 3(4), 1597-614. https://doi.org/10.3390/brainsci3041597
Serafini, Sandra, et al. "Reorganization and stability for motor and language areas using cortical stimulation: case example and review of the literature." Brain sciences vol. 3,4 (2013): 1597-614. doi: https://doi.org/10.3390/brainsci3041597
Serafini S, Komisarow JM, Gallentine W, Mikati MA, Bonner MJ, Kranz PG, Haglund MM, Grant G. Reorganization and stability for motor and language areas using cortical stimulation: case example and review of the literature. Brain Sci. 2013 Nov 26;3(4):1597-614. doi: 10.3390/brainsci3041597. PMID: 24961623; PMCID: PMC4061887.
Copy Download .nbib Format: NLM
Corrigendum to "Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature" [Seizure 55 (February) (2018) 1-3].

Seizure

Abdelnour E, Gallentine W, McDonald M, Sachdev M, Jiang YH, Mikati MA.
PMID: 31072785
Seizure. 2019 Jul;69:305. doi: 10.1016/j.seizure.2019.04.014. Epub 2019 May 06.

No abstract available.

Cite
Abdelnour E, Gallentine W, McDonald M, et al. Corrigendum to "Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature" [Seizure 55 (February) (2018) 1-3]. Seizure. 2019;69:305doi: 10.1016/j.seizure.2019.04.014.
Abdelnour, E., Gallentine, W., McDonald, M., Sachdev, M., Jiang, Y. H., & Mikati, M. A. (2019). Corrigendum to "Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature" [Seizure 55 (February) (2018) 1-3]. Seizure, 69305. https://doi.org/10.1016/j.seizure.2019.04.014
Abdelnour, Elie, et al. "Corrigendum to "Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature" [Seizure 55 (February) (2018) 1-3]." Seizure vol. 69 (2019): 305. doi: https://doi.org/10.1016/j.seizure.2019.04.014
Abdelnour E, Gallentine W, McDonald M, Sachdev M, Jiang YH, Mikati MA. Corrigendum to "Does age affect response to quinidine in patients with KCNT1 mutations? Report of three new cases and review of the literature" [Seizure 55 (February) (2018) 1-3]. Seizure. 2019 Jul;69:305. doi: 10.1016/j.seizure.2019.04.014. Epub 2019 May 06. PMID: 31072785.
Copy Download .nbib Format: NLM
Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders.

Genome medicine

Gillentine MA, Wang T, Hoekzema K, Rosenfeld J, Liu P, Guo H, Kim CN, De Vries BBA, Vissers LELM, Nordenskjold M, Kvarnung M, Lindstrand A, Nordgren A, Gecz J, Iascone M, Cereda A, Scatigno A, Maitz S, Zanni G, Bertini E, Zweier C, Schuhmann S, Wiesener A, Pepper M, Panjwani H, Torti E, Abid F, Anselm I, Srivastava S, Atwal P, Bacino CA, Bhat G, Cobian K, Bird LM, Friedman J, Wright MS, Callewaert B, Petit F, Mathieu S, Afenjar A, Christensen CK, White KM, Elpeleg O, Berger I, Espineli EJ, Fagerberg C, Brasch-Andersen C, Hansen LK, Feyma T, Hughes S, Thiffault I, Sullivan B, Yan S, Keller K, Keren B, Mignot C, Kooy F, Meuwissen M, Basinger A, Kukolich M, Philips M, Ortega L, Drummond-Borg M, Lauridsen M, Sorensen K, Lehman A, Lopez-Rangel E, Levy P, Lessel D, Lotze T, Madan-Khetarpal S, Sebastian J, Vento J, Vats D, Benman LM, Mckee S, Mirzaa GM, Muss C, Pappas J, Peeters H, Romano C, Elia M, Galesi O, Simon MEH, van Gassen KLI, Simpson K, Stratton R, Syed S, Thevenon J, Palafoll IV, Vitobello A, Bournez M, Faivre L, Xia K, Earl RK, Nowakowski T, Bernier RA, Eichler EE.
PMID: 33874999
Genome Med. 2021 Apr 19;13(1):63. doi: 10.1186/s13073-021-00870-6.

BACKGROUND: With the increasing number of genomic sequencing studies, hundreds of genes have been implicated in neurodevelopmental disorders (NDDs). The rate of gene discovery far outpaces our understanding of genotype-phenotype correlations, with clinical characterization remaining a bottleneck for understanding...

Cite
Gillentine MA, Wang T, Hoekzema K, et al. Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders. Genome Med. 2021;13(1):63doi: 10.1186/s13073-021-00870-6.
Gillentine, M. A., Wang, T., Hoekzema, K., Rosenfeld, J., Liu, P., Guo, H., Kim, C. N., De Vries, B. B. A., Vissers, L. E. L. M., Nordenskjold, M., Kvarnung, M., Lindstrand, A., Nordgren, A., Gecz, J., Iascone, M., Cereda, A., Scatigno, A., Maitz, S., Zanni, G., Bertini, E., Zweier, C., Schuhmann, S., Wiesener, A., Pepper, M., Panjwani, H., Torti, E., Abid, F., Anselm, I., Srivastava, S., Atwal, P., Bacino, C. A., Bhat, G., Cobian, K., Bird, L. M., Friedman, J., Wright, M. S., Callewaert, B., Petit, F., Mathieu, S., Afenjar, A., Christensen, C. K., White, K. M., Elpeleg, O., Berger, I., Espineli, E. J., Fagerberg, C., Brasch-Andersen, C., Hansen, L. K., Feyma, T., Hughes, S., Thiffault, I., Sullivan, B., Yan, S., Keller, K., Keren, B., Mignot, C., Kooy, F., Meuwissen, M., Basinger, A., Kukolich, M., Philips, M., Ortega, L., Drummond-Borg, M., Lauridsen, M., Sorensen, K., Lehman, A., Lopez-Rangel, E., Levy, P., Lessel, D., Lotze, T., Madan-Khetarpal, S., Sebastian, J., Vento, J., Vats, D., Benman, L. M., Mckee, S., Mirzaa, G. M., Muss, C., Pappas, J., Peeters, H., Romano, C., Elia, M., Galesi, O., Simon, M. E. H., van Gassen, K. L. I., Simpson, K., Stratton, R., Syed, S., Thevenon, J., Palafoll, I. V., Vitobello, A., Bournez, M., Faivre, L., Xia, K., Earl, R. K., Nowakowski, T., Bernier, R. A., & Eichler, E. E. (2021). Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders. Genome medicine, 13(1), 63. https://doi.org/10.1186/s13073-021-00870-6
Gillentine, Madelyn A, et al. "Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders." Genome medicine vol. 13,1 (2021): 63. doi: https://doi.org/10.1186/s13073-021-00870-6
Gillentine MA, Wang T, Hoekzema K, Rosenfeld J, Liu P, Guo H, Kim CN, De Vries BBA, Vissers LELM, Nordenskjold M, Kvarnung M, Lindstrand A, Nordgren A, Gecz J, Iascone M, Cereda A, Scatigno A, Maitz S, Zanni G, Bertini E, Zweier C, Schuhmann S, Wiesener A, Pepper M, Panjwani H, Torti E, Abid F, Anselm I, Srivastava S, Atwal P, Bacino CA, Bhat G, Cobian K, Bird LM, Friedman J, Wright MS, Callewaert B, Petit F, Mathieu S, Afenjar A, Christensen CK, White KM, Elpeleg O, Berger I, Espineli EJ, Fagerberg C, Brasch-Andersen C, Hansen LK, Feyma T, Hughes S, Thiffault I, Sullivan B, Yan S, Keller K, Keren B, Mignot C, Kooy F, Meuwissen M, Basinger A, Kukolich M, Philips M, Ortega L, Drummond-Borg M, Lauridsen M, Sorensen K, Lehman A, Lopez-Rangel E, Levy P, Lessel D, Lotze T, Madan-Khetarpal S, Sebastian J, Vento J, Vats D, Benman LM, Mckee S, Mirzaa GM, Muss C, Pappas J, Peeters H, Romano C, Elia M, Galesi O, Simon MEH, van Gassen KLI, Simpson K, Stratton R, Syed S, Thevenon J, Palafoll IV, Vitobello A, Bournez M, Faivre L, Xia K, Earl RK, Nowakowski T, Bernier RA, Eichler EE. Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders. Genome Med. 2021 Apr 19;13(1):63. doi: 10.1186/s13073-021-00870-6. PMID: 33874999; PMCID: PMC8056596.
Copy Download .nbib Format: NLM
Author Correction: Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders.

Nature communications

Wang T, Hoekzema K, Vecchio D, Wu H, Sulovari A, Coe BP, Gillentine MA, Wilfert AB, Perez-Jurado LA, Kvarnung M, Sleyp Y, Earl RK, Rosenfeld JA, Geisheker MR, Han L, Du B, Barnett C, Thompson E, Shaw M, Carroll R, Friend K, Catford R, Palmer EE, Zou X, Ou J, Li H, Guo H, Gerdts J, Avola E, Calabrese G, Elia M, Greco D, Lindstrand A, Nordgren A, Anderlid BM, Vandeweyer G, Van Dijck A, Van der Aa N, McKenna B, Hancarova M, Bendova S, Havlovicova M, Malerba G, Bernardina BD, Muglia P, van Haeringen A, Hoffer MJV, Franke B, Cappuccio G, Delatycki M, Lockhart PJ, Manning MA, Liu P, Scheffer IE, Brunetti-Pierri N, Rommelse N, Amaral DG, Santen GWE, Trabetti E, Sedláček Z, Michaelson JJ, Pierce K, Courchesne E, Kooy RF, Nordenskjöld M, Romano C, Peeters H, Bernier RA, Gecz J, Xia K, Eichler EE.
PMID: 33087701
Nat Commun. 2020 Oct 21;11(1):5398. doi: 10.1038/s41467-020-19289-5.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Wang T, Hoekzema K, Vecchio D, et al. Author Correction: Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat Commun. 2020;11(1):5398doi: 10.1038/s41467-020-19289-5.
Wang, T., Hoekzema, K., Vecchio, D., Wu, H., Sulovari, A., Coe, B. P., Gillentine, M. A., Wilfert, A. B., Perez-Jurado, L. A., Kvarnung, M., Sleyp, Y., Earl, R. K., Rosenfeld, J. A., Geisheker, M. R., Han, L., Du, B., Barnett, C., Thompson, E., Shaw, M., Carroll, R., Friend, K., Catford, R., Palmer, E. E., Zou, X., Ou, J., Li, H., Guo, H., Gerdts, J., Avola, E., Calabrese, G., Elia, M., Greco, D., Lindstrand, A., Nordgren, A., Anderlid, B. M., Vandeweyer, G., Van Dijck, A., Van der Aa, N., McKenna, B., Hancarova, M., Bendova, S., Havlovicova, M., Malerba, G., Bernardina, B. D., Muglia, P., van Haeringen, A., Hoffer, M. J. V., Franke, B., Cappuccio, G., Delatycki, M., Lockhart, P. J., Manning, M. A., Liu, P., Scheffer, I. E., Brunetti-Pierri, N., Rommelse, N., Amaral, D. G., Santen, G. W. E., Trabetti, E., Sedláček, Z., Michaelson, J. J., Pierce, K., Courchesne, E., Kooy, R. F., Nordenskjöld, M., Romano, C., Peeters, H., Bernier, R. A., Gecz, J., Xia, K., & Eichler, E. E. (2020). Author Correction: Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nature communications, 11(1), 5398. https://doi.org/10.1038/s41467-020-19289-5
Wang, Tianyun, et al. "Author Correction: Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders." Nature communications vol. 11,1 (2020): 5398. doi: https://doi.org/10.1038/s41467-020-19289-5
Wang T, Hoekzema K, Vecchio D, Wu H, Sulovari A, Coe BP, Gillentine MA, Wilfert AB, Perez-Jurado LA, Kvarnung M, Sleyp Y, Earl RK, Rosenfeld JA, Geisheker MR, Han L, Du B, Barnett C, Thompson E, Shaw M, Carroll R, Friend K, Catford R, Palmer EE, Zou X, Ou J, Li H, Guo H, Gerdts J, Avola E, Calabrese G, Elia M, Greco D, Lindstrand A, Nordgren A, Anderlid BM, Vandeweyer G, Van Dijck A, Van der Aa N, McKenna B, Hancarova M, Bendova S, Havlovicova M, Malerba G, Bernardina BD, Muglia P, van Haeringen A, Hoffer MJV, Franke B, Cappuccio G, Delatycki M, Lockhart PJ, Manning MA, Liu P, Scheffer IE, Brunetti-Pierri N, Rommelse N, Amaral DG, Santen GWE, Trabetti E, Sedláček Z, Michaelson JJ, Pierce K, Courchesne E, Kooy RF, Nordenskjöld M, Romano C, Peeters H, Bernier RA, Gecz J, Xia K, Eichler EE. Author Correction: Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nat Commun. 2020 Oct 21;11(1):5398. doi: 10.1038/s41467-020-19289-5. PMID: 33087701; PMCID: PMC7578800.
Copy Download .nbib Format: NLM
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.

JAMA neurology

Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK.
PMID: 34542573
JAMA Neurol. 2021 Nov 01;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188.

IMPORTANCE: Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear.OBJECTIVE: To map the use and safety of immunotherapies...

Cite
Nosadini M, Eyre M, Molteni E, et al. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021;78(11):1333-1344doi: 10.1001/jamaneurol.2021.3188.
Nosadini, M., Eyre, M., Molteni, E., Thomas, T., Irani, S. R., Dalmau, J., Dale, R. C., Lim, M., Anlar, B., Armangue, T., Benseler, S., Cellucci, T., Deiva, K., Gallentine, W., Gombolay, G., Gorman, M. P., Hacohen, Y., Jiang, Y., Lim, B. C., Muscal, E., Ndondo, A., Neuteboom, R., Rostásy, K., Sakuma, H., Sartori, S., Sharma, S., Tenembaum, S. N., Van Mater, H. A., Wells, E., Wickstrom, R., & Yeshokumar, A. K. (2021). Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA neurology, 78(11), 1333-1344. https://doi.org/10.1001/jamaneurol.2021.3188
Nosadini, Margherita, et al. "Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis." JAMA neurology vol. 78,11 (2021): 1333-1344. doi: https://doi.org/10.1001/jamaneurol.2021.3188
Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 Nov 01;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188. PMID: 34542573; PMCID: PMC8453367.
Copy Download .nbib Format: NLM
Performance enhancement in color deficiency with color-correcting lenses.

Eye (London, England)

Rabin J, Silva F, Trevino N, Gillentine H, Li L, Inclan L, Anderson G, Lee E, Vo H.
PMID: 34999724
Eye (Lond). 2022 Jan 08; doi: 10.1038/s41433-021-01924-0. Epub 2022 Jan 08.

No abstract available.

Cite
Rabin J, Silva F, Trevino N, et al. Performance enhancement in color deficiency with color-correcting lenses. Eye (Lond). 2022;doi: 10.1038/s41433-021-01924-0.
Rabin, J., Silva, F., Trevino, N., Gillentine, H., Li, L., Inclan, L., Anderson, G., Lee, E., & Vo, H. (2022). Performance enhancement in color deficiency with color-correcting lenses. Eye (London, England), . https://doi.org/10.1038/s41433-021-01924-0
Rabin, Jeff, et al. "Performance enhancement in color deficiency with color-correcting lenses." Eye (London, England) vol. (2022). doi: https://doi.org/10.1038/s41433-021-01924-0
Rabin J, Silva F, Trevino N, Gillentine H, Li L, Inclan L, Anderson G, Lee E, Vo H. Performance enhancement in color deficiency with color-correcting lenses. Eye (Lond). 2022 Jan 08; doi: 10.1038/s41433-021-01924-0. Epub 2022 Jan 08. PMID: 34999724.
Copy Download .nbib Format: NLM
Third-degree burn on the neuropathic lower extremity in a patient with diabetes while wearing a copper-containing compression sock: a case report.

Wound management & prevention

Gallentine A.
PMID: 35030541
Wound Manag Prev. 2021 Dec;67(12):26-29.

BACKGROUND: Many patients who have diabetes and peripheral neuropathy wear compression socks, which are widely available and may be purchased with a copper component. There is also a well-documented history of patients with neuropathy developing thermal burns from heat...

Cite
Gallentine A. Third-degree burn on the neuropathic lower extremity in a patient with diabetes while wearing a copper-containing compression sock: a case report. Wound Manag Prev. 2021;67(12):26-29
Gallentine, A. (2021). Third-degree burn on the neuropathic lower extremity in a patient with diabetes while wearing a copper-containing compression sock: a case report. Wound management & prevention, 67(12), 26-29.
Gallentine, Anne. "Third-degree burn on the neuropathic lower extremity in a patient with diabetes while wearing a copper-containing compression sock: a case report." Wound management & prevention vol. 67,12 (2021): 26-29.
Gallentine A. Third-degree burn on the neuropathic lower extremity in a patient with diabetes while wearing a copper-containing compression sock: a case report. Wound Manag Prev. 2021 Dec;67(12):26-29. PMID: 35030541.
Copy Download .nbib Format: NLM
Performance enhancement in color deficiency with color-correcting lenses.

Eye (London, England)

Rabin J, Silva F, Trevino N, Gillentine H, Li L, Inclan L, Anderson G, Lee E, Vo H.
PMID: 34999724
Eye (Lond). 2022 Jan 08; doi: 10.1038/s41433-021-01924-0. Epub 2022 Jan 08.

No abstract available.

Cite
Rabin J, Silva F, Trevino N, et al. Performance enhancement in color deficiency with color-correcting lenses. Eye (Lond). 2022;doi: 10.1038/s41433-021-01924-0.
Rabin, J., Silva, F., Trevino, N., Gillentine, H., Li, L., Inclan, L., Anderson, G., Lee, E., & Vo, H. (2022). Performance enhancement in color deficiency with color-correcting lenses. Eye (London, England), . https://doi.org/10.1038/s41433-021-01924-0
Rabin, Jeff, et al. "Performance enhancement in color deficiency with color-correcting lenses." Eye (London, England) vol. (2022). doi: https://doi.org/10.1038/s41433-021-01924-0
Rabin J, Silva F, Trevino N, Gillentine H, Li L, Inclan L, Anderson G, Lee E, Vo H. Performance enhancement in color deficiency with color-correcting lenses. Eye (Lond). 2022 Jan 08; doi: 10.1038/s41433-021-01924-0. Epub 2022 Jan 08. PMID: 34999724.
Copy Download .nbib Format: NLM
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis.

Neurology(R) neuroimmunology & neuroinflammation

Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK, Irani SR, Dalmau J, Lim M, Dale RC.
PMID: 34301820
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 22;8(5). doi: 10.1212/NXI.0000000000001052. Print 2021 Jul.

OBJECTIVE: To create an international consensus treatment recommendation for pediatric NMDA receptor antibody encephalitis (NMDARE).METHODS: After selection of a panel of 27 experts with representation from all continents, a 2-step Delphi method was adopted to develop consensus on relevant...

Cite
Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(5)doi: 10.1212/NXI.0000000000001052.
Nosadini, M., Thomas, T., Eyre, M., Anlar, B., Armangue, T., Benseler, S. M., Cellucci, T., Deiva, K., Gallentine, W., Gombolay, G., Gorman, M. P., Hacohen, Y., Jiang, Y., Lim, B. C., Muscal, E., Ndondo, A., Neuteboom, R., Rostásy, K., Sakuma, H., Sharma, S., Tenembaum, S. N., Van Mater, H. A., Wells, E., Wickstrom, R., Yeshokumar, A. K., Irani, S. R., Dalmau, J., Lim, M., & Dale, R. C. (2021). International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurology(R) neuroimmunology & neuroinflammation, 8(5), . https://doi.org/10.1212/NXI.0000000000001052
Nosadini, Margherita, et al. "International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis." Neurology(R) neuroimmunology & neuroinflammation vol. 8,5 (2021). doi: https://doi.org/10.1212/NXI.0000000000001052
Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK, Irani SR, Dalmau J, Lim M, Dale RC. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 22;8(5). doi: 10.1212/NXI.0000000000001052. Print 2021 Jul. PMID: 34301820; PMCID: PMC8299516.
Copy Download .nbib Format: NLM
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.

JAMA neurology

Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK.
PMID: 34542573
JAMA Neurol. 2021 Nov 01;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188.

IMPORTANCE: Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear.OBJECTIVE: To map the use and safety of immunotherapies...

Cite
Nosadini M, Eyre M, Molteni E, et al. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021;78(11):1333-1344doi: 10.1001/jamaneurol.2021.3188.
Nosadini, M., Eyre, M., Molteni, E., Thomas, T., Irani, S. R., Dalmau, J., Dale, R. C., Lim, M., Anlar, B., Armangue, T., Benseler, S., Cellucci, T., Deiva, K., Gallentine, W., Gombolay, G., Gorman, M. P., Hacohen, Y., Jiang, Y., Lim, B. C., Muscal, E., Ndondo, A., Neuteboom, R., Rostásy, K., Sakuma, H., Sartori, S., Sharma, S., Tenembaum, S. N., Van Mater, H. A., Wells, E., Wickstrom, R., & Yeshokumar, A. K. (2021). Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA neurology, 78(11), 1333-1344. https://doi.org/10.1001/jamaneurol.2021.3188
Nosadini, Margherita, et al. "Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis." JAMA neurology vol. 78,11 (2021): 1333-1344. doi: https://doi.org/10.1001/jamaneurol.2021.3188
Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol. 2021 Nov 01;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188. PMID: 34542573; PMCID: PMC8453367.
Copy Download .nbib Format: NLM
Erratum to: The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications.

Journal of autism and developmental disorders

Gillentine MA, Berry LN, Goin-Kochel RP, Ali MA, Ge J, Guffey D, Rosenfeld JA, Hannig V, Bader P, Proud M, Shinawi M, Graham BH, Lin A, Lalani SR, Reynolds J, Chen M, Grebe T, Minard CG, Stankiewicz P, Beaudet AL, Schaaf CP.
PMID: 28168676
J Autism Dev Disord. 2017 Mar;47(3):563. doi: 10.1007/s10803-017-3047-y.

No abstract available.

Cite
Gillentine MA, Berry LN, Goin-Kochel RP, et al. Erratum to: The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications. J Autism Dev Disord. 2017;47(3):563doi: 10.1007/s10803-017-3047-y.
Gillentine, M. A., Berry, L. N., Goin-Kochel, R. P., Ali, M. A., Ge, J., Guffey, D., Rosenfeld, J. A., Hannig, V., Bader, P., Proud, M., Shinawi, M., Graham, B. H., Lin, A., Lalani, S. R., Reynolds, J., Chen, M., Grebe, T., Minard, C. G., Stankiewicz, P., Beaudet, A. L., & Schaaf, C. P. (2017). Erratum to: The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications. Journal of autism and developmental disorders, 47(3), 563. https://doi.org/10.1007/s10803-017-3047-y
Gillentine, M A, et al. "Erratum to: The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications." Journal of autism and developmental disorders vol. 47,3 (2017): 563. doi: https://doi.org/10.1007/s10803-017-3047-y
Gillentine MA, Berry LN, Goin-Kochel RP, Ali MA, Ge J, Guffey D, Rosenfeld JA, Hannig V, Bader P, Proud M, Shinawi M, Graham BH, Lin A, Lalani SR, Reynolds J, Chen M, Grebe T, Minard CG, Stankiewicz P, Beaudet AL, Schaaf CP. Erratum to: The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications. J Autism Dev Disord. 2017 Mar;47(3):563. doi: 10.1007/s10803-017-3047-y. PMID: 28168676.
Copy Download .nbib Format: NLM
The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.

European urology

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter BH.
PMID: 19884959
Eur Urol. 2008 Nov;54(5):978-979. doi: 10.1016/j.eururo.2008.07.069. Epub 2008 Aug 03.

No abstract available.

Cite
Loeb S, Kettermann A, Ferrucci L, et al. The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. Eur Urol. 2008;54(5):978-979doi: 10.1016/j.eururo.2008.07.069.
Loeb, S., Kettermann, A., Ferrucci, L., Landis, P., Metter, E. J., & Carter, B. H. (2008). The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. European urology, 54(5), 978-979. https://doi.org/10.1016/j.eururo.2008.07.069
Loeb, Stacy, et al. "The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease." European urology vol. 54,5 (2008): 978-979. doi: https://doi.org/10.1016/j.eururo.2008.07.069
Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter BH. The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease. Eur Urol. 2008 Nov;54(5):978-979. doi: 10.1016/j.eururo.2008.07.069. Epub 2008 Aug 03. PMID: 19884959; PMCID: PMC2603630.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries